Diabetic ketoacidosis after the second dose of SARS-CoV-2 mRNA vaccination in a patient with pembrolizumab-induced fulminant type 1 diabetes

We report a case of 77-year-old woman with fulminant type 1 diabetes (T1D) who developed diabetic ketoacidosis (DKA) after the second dose of SARS-CoV-2 vaccine tozinameran. The patient had been diagnosed as having T1D associated with an immune-related adverse event caused by pembrolizumab at the ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Kohei, Nakagawa, Kimiko, Yase, Eriko, Terashima, Mariko, Murata, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780095/
https://www.ncbi.nlm.nih.gov/pubmed/36575722
http://dx.doi.org/10.1007/s13340-022-00614-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780095/
https://www.ncbi.nlm.nih.gov/pubmed/36575722
http://dx.doi.org/10.1007/s13340-022-00614-w

Ejemplares similares